

Technology Advisory Committee A Interests Register

Tirzepatide for managing overweight and obesity [ID6179]

Publication Date: 19 June 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Matthew Capehorn	Clinical Expert	Direct financial interest	Received research funding from Lilly, Novo Nordisk, and Boehringer in the last 12m together with honoraria for speaking for these companies and attending advisory board meetings. I have also benefitted from funding to attend conferences.	09/04/2024	It was agreed that Matthew's declaration would not prevent him from providing expert advice to the committee.
Sarah Le Brocq	Patient Expert	Direct – financial	Sarah delivered a presentation to Eli Lilly internal commercial team, of my lived experience of living with obesity. To help educate the commercial team on the realities of obesity. She was paid an honorarium for her presentation. This took place on 16 January 2024.	16/01/2024	It was agreed that Sarah's declaration would not prevent her from providing expert advice to the committee.
Sarah Le Brocq	Patient Expert	Direct – financial	Received honorarium payments for speaking events and training from Novo Nordisk. Lilly have supported AAO as a corporate sponsorship member for the past 12 months. Sarah received honorarium payments for speaking events and training from Novo Nordisk	09/04/2024 06/07/2023	It was agreed that Sarah's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Matthew Capehorn	Clinical Expert	Direct financial interest	Received research funding from Lilly, Novo Nordisk, and Boehringer in the last 12m together with honoraria for speaking for these companies and attending advisory board meetings. I have also benefitted from funding to attend conferences.	09/04/2024	It was agreed that Matthew's declaration would not prevent him from providing expert advice to the committee.
			Lilly have supported AAO as a corporate sponsorship member for the past 12 months.		
Sarah Le Brocq	Patient Expert	Direct – non-financial	Sarah sits on the strategic council for the APPG for obesity Sarah is a Trustee at ASO Sarah is a member of the NHSE National Obesity Audit steering group	09/04/2024 06/07/2023	It was agreed that Sarah's declaration would not prevent her from providing expert advice to the committee.
Dr Dimitris Papamargaritis	Clinical Expert	Direct – financial	Novo Nordisk: Dimitris received honoraria for educational events and research grant support. He was co-investigator for an investigator initiated clinical trial funded by Novo Nordisk between 11/2017 and 12/2022 (https://classic.clinicaltrials.gov/ct2/show/NCT03036800). The study assessed the clinical effectiveness of liraglutide 3mg in Tier 3 weight management services when used with a targeted prescribing pathway with	09/04/2024 03/07/2023	It was agreed that Dimitris' declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Matthew Capehorn	Clinical Expert	Direct financial interest	Received research funding from Lilly, Novo Nordisk, and Boehringer in the last 12m together with honoraria for speaking for these companies and attending advisory board meetings. I have also benefitted from funding to attend conferences.	09/04/2024	It was agreed that Matthew's declaration would not prevent him from providing expert advice to the committee.
			multiple stopping rules compared to standard care in Tier 3 weight management services. Academy of Medical Sciences/ Diabetes UK: Dimitris received research grant support (£29,944) between 06/2019 and 06/2022. Health Education East Midlands: Dimitris received research grant support (£9,985) between 02/2020 and 08/2022.		
Dr Dimitris Papamargaritis	Clinical Expert	Direct – non-financial	Trustee of the Association for the Study of Obesity (08/12/2022) Member of the Academic subcommittee for the Association of British Clinical Diabetologists (08/06/2021) Member of the Research Grant subcommittee for the Association of British Clinical Diabetologists (08/06/2021)	09/04/2024 03/07/2023	It was agreed that Dimitris' declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Matthew Capehorn	Clinical Expert	Direct financial interest	Received research funding from Lilly, Novo Nordisk, and Boehringer in the last 12m together with honoraria for speaking for these companies and attending advisory board meetings. I have also benefitted from funding to attend conferences.	09/04/2024	It was agreed that Matthew's declaration would not prevent him from providing expert advice to the committee.
			Co-founder of the Diabetes Update course, organised by the Association of British Clinical Diabetologists Contributed to ASO comments submission at the scoping consultation invitation for ID6179 (tirzepatide for people with overweight/obesity)		
Dr Dimitris Papamargaritis	Clinical Expert	Indirect	Working in Leicester Diabetes Centre where we host a national patient recruitment centre and multiple studies with new obesity and diabetes pharmacotherapies (including tirzepatide and cagri-sema) are taking place with principal investigator Prof Melanie Davies.	09/04/2024 03/07/2023	It was agreed that Dimitris' declaration would not prevent him from providing expert advice to the committee.

